Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian P Kells

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Neuroscience Letters|April 15, 2008
AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioningAdrian P Kells, Bronwen Connor
Neurobiology of Disease|October 25, 2011
Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brainAdrian P Kells, John Forsayeth, Krystof S Bankiewicz
Journal of Neuroscience Methods|December 21, 2006
Verification of functional AAV-mediated neurotrophic and anti-apoptotic factor expressionAdrian P Kells, Rebecca A Henry, Stephanie M Hughes, et al.
Advanced Drug Delivery Reviews|November 1, 2011
Guided delivery of adeno-associated viral vectors into the primate brainErnesto A Salegio, Lluis Samaranch, Adrian P Kells, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 24, 2013
Gene therapy for misfolding protein diseases of the central nervous systemWaldy San Sebastian, Lluis Samaranch, Adrian P Kells, et al.
International Journal of Toxicology|November 2, 2020
Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's DiseasePramod S Terse, Adrian P Kells, Patricia Noker, et al.
Progress in Brain Research|August 8, 2009
Controlled dissemination of AAV vectors in the primate brainVanja Varenika, Adrian P Kells, Francisco Valles, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 25, 2010
Anterograde axonal transport of AAV2-GDNF in rat basal gangliaAgnieszka Ciesielska, Gabriele Mittermeyer, Piotr Hadaczek, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2004
AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington diseaseAdrian P Kells, Dahna M Fong, Mike Dragunow, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2009
Efficient gene therapy-based method for the delivery of therapeutics to primate cortexAdrian P Kells, Piotr Hadaczek, Dali Yin, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Neuroscience Letters|April 15, 2008
AAV-mediated expression of Bcl-xL or XIAP fails to induce neuronal resistance against quinolinic acid-induced striatal lesioningAdrian P Kells, Bronwen Connor
Neurobiology of Disease|October 25, 2011
Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brainAdrian P Kells, John Forsayeth, Krystof S Bankiewicz
Journal of Neuroscience Methods|December 21, 2006
Verification of functional AAV-mediated neurotrophic and anti-apoptotic factor expressionAdrian P Kells, Rebecca A Henry, Stephanie M Hughes, et al.
Advanced Drug Delivery Reviews|November 1, 2011
Guided delivery of adeno-associated viral vectors into the primate brainErnesto A Salegio, Lluis Samaranch, Adrian P Kells, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|May 24, 2013
Gene therapy for misfolding protein diseases of the central nervous systemWaldy San Sebastian, Lluis Samaranch, Adrian P Kells, et al.
International Journal of Toxicology|November 2, 2020
Safety Assessment of AAV2-hGDNF Administered Via Intracerebral Injection in Rats for Treatment of Parkinson's DiseasePramod S Terse, Adrian P Kells, Patricia Noker, et al.
Progress in Brain Research|August 8, 2009
Controlled dissemination of AAV vectors in the primate brainVanja Varenika, Adrian P Kells, Francisco Valles, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 25, 2010
Anterograde axonal transport of AAV2-GDNF in rat basal gangliaAgnieszka Ciesielska, Gabriele Mittermeyer, Piotr Hadaczek, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 4, 2004
AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington diseaseAdrian P Kells, Dahna M Fong, Mike Dragunow, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2009
Efficient gene therapy-based method for the delivery of therapeutics to primate cortexAdrian P Kells, Piotr Hadaczek, Dali Yin, et al.
Pageof 4